Compare Abbott Laboratories (ABT) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Oxford Lane Capital Corp — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while Oxford Lane Capital Corp trades at $9 (market cap $872.99M). The key difference: Abbott Laboratories is far larger — about 191.2× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.85%). Which is the better fit depends on your goals.
| ABT | OXLC | |
|---|---|---|
Market Cap | $166.94B | $872.99M |
Sector | Health | Financials |
52-Week High | $136.62 | $20.80 |
52-Week Low | $82.57 | $8.15 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 26.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
OXLC trades at $8.95, up 1.59% today, with a bullish technical signal but mixed indicators. The stock shows a P/B of 0.85, suggesting potential undervaluation, but profitability metrics are weak with a -39.16% ROE. Recent earnings have consistently missed expectations, including a significant Q1 2026 EPS miss. The company maintains a regular dividend payout of $0.20 per share, supporting income-focused investors despite fundamental challenges.
Outlook remains cautious due to persistent earnings underperformance and negative ROE/ROA. High dividend yield attracts income seekers, but sustainability concerns and NAV declines pose risks. Analyst consensus is divided, with 50% buy ratings balanced by bearish sentiment from financial media. Key risks include further NAV erosion and reliance on financing cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
